PROF Stock Overview
Operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Profound Medical Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$8.20 |
| 52 Week High | CA$11.69 |
| 52 Week Low | CA$7.11 |
| Beta | 0.80 |
| 11 Month Change | 4.86% |
| 3 Month Change | -13.23% |
| 1 Year Change | -13.14% |
| 33 Year Change | -34.50% |
| 5 Year Change | -6.92% |
| Change since IPO | -19.49% |
Recent News & Updates
Shareholder Returns
| PROF | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 8.8% | 0.3% | -1.9% |
| 1Y | -13.1% | 25.8% | 30.4% |
Return vs Industry: PROF underperformed the US Medical Equipment industry which returned 25.8% over the past year.
Return vs Market: PROF underperformed the US Market which returned 30.8% over the past year.
Price Volatility
| PROF volatility | |
|---|---|
| PROF Average Weekly Movement | 6.6% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: PROF has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PROF's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 131 | Arun Menawat | www.profoundmedical.com |
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors.
Profound Medical Corp. Fundamentals Summary
| PROF fundamental statistics | |
|---|---|
| Market cap | US$182.71m |
| Earnings (TTM) | -US$27.59m |
| Revenue (TTM) | US$7.88m |
25.6x
P/S Ratio-7.3x
P/E RatioIs PROF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PROF income statement (TTM) | |
|---|---|
| Revenue | US$7.88m |
| Cost of Revenue | US$3.05m |
| Gross Profit | US$4.83m |
| Other Expenses | US$32.42m |
| Earnings | -US$27.59m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
| Earnings per share (EPS) | -1.12 |
| Gross Margin | 61.24% |
| Net Profit Margin | -350.14% |
| Debt/Equity Ratio | 15.2% |
How did PROF perform over the long term?
See historical performance and comparison